Press Release

As the novel coronavirus (COVID-19) continues to spread across the world, our analysts are constantly tracking the impact of this rapidly evolving situation on the markets and the consumer purchase behaviours. Thus, our latest estimates and analysis about the current market trends and forecast will exhaustively reflect the effects of this emerging pandemic.

Global Giant Cell Arteritis Treatment Market to Grow at a CAGR of 5.1% During 2021-2026, Aided by the Rising Elderly Population

According to a new report by EMR titled, ‘Global Giant Cell Arteritis Treatment Market Report and Forecast 2021-2026’, the global market for giant cell arteritis treatment is expected to grow at a CAGR of 5.1% in the forecast period of 2021-2026.

North America and Europe are expected to be key markets for giant cell arteritis treatment owing to the high living standards and health awareness among the consumers. The growing health care industry in China and India is driving the market in the Asia Pacific region.

The giant cell arteritis treatment mainly consists of high doses of a corticosteroid drug, such as prednisone. Currently available treatments focus on minimising tissue damage caused by inadequate blood flow. Leading players in the global giant cell arteritis treatment industry, such as JF. Hoffmann-La Roche Ltd., Kiniksa Pharmaceuticals, Ltd., Teva Pharmaceutical Industries Ltd., and Tianjin Tianyao Pharmaceutical Co., Ltd., are investing heavily in the research and development activities to develop effective treatments for such autoimmune diseases. Significant technological advancements and the adoption of sonographic assessments are expected to create strong opportunities for market growth.

The approval of orphan drug status to newly developed drugs for the treatment of giant cell arteritis treatment by regulatory authorities like the U.S. Food and Drug Administration (FDA) is also expected to boost the market growth by promoting further drug development through financial incentives and user fee waivers. In September 2020, Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA), a major biopharmaceutical company, announced that FDA had granted mavrilimumab an Orphan Drug designation to be used in the giant cell arteritis treatment. The company was also expected to announce the data from its phase 2 study of mavrilimumab for the treatment of giant cell arteritis treatment by Q4 2020.

Market Analysis by Type, End Use, and Region:

  • The market based on type can be divided into corticosteroid therapy and adjuvant agents.
  • The end-uses for giant cell arteritis treatment include hospitals, clinics, and ASC’s, among others. 
  • The regional markets for giant cell arteritis treatment include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

Key Findings of the Report:

  • The market is being driven by the rising prevalence of autoimmune diseases across the globe.
  • The rising aged population and the growing health awareness are adding to market growth.
  • The growing investments by governments across the globe in the R&D activities of the healthcare industry are aiding the market. 
  • Furthermore, the increasing disposable incomes and the growing urbanisation are providing an impetus for market growth.

Key Offerings of the Report:

  • The EMR report gives an overview of the global market for giant cell arteritis treatment for the periods (2016-2020) and (2021-2026).
  • The report also offers the historical (2016-2020) and forecast (2021-2026) markets for the types, end-uses, and major regions of giant cell arteritis treatment.
  • The report analyses the market dynamics, covering the key demand and price indicators in the market, along with an assessment of the SWOT and Porter’s Five Forces models.

The major players in the global giant cell arteritis treatment market include Johns Hopkins Hospital, American College of Rheumatology, Duke University Health System, and Lahey Clinic Foundation, Inc., among others. The comprehensive report by EMR looks into the market share, capacity, and latest developments like mergers and acquisitions, plant turnarounds, and capacity expansions of the major players.

About Us:

Expert Market Research (EMR) is a leading market research and business intelligence company, ensuring its clients remain at the vanguard of their industries by providing them with exhaustive and actionable market data through its syndicated and custom market reports, covering over 15 major industry domains. The company's expansive and ever-growing database of reports, which are constantly updated, includes reports from industry verticals like chemicals and materials, food and beverages, energy and mining, technology and media, consumer goods, pharmaceuticals, agriculture, and packaging.

EMR leverages its state-of-the-art technological and analytical tools, along with the expertise of its highly skilled team of over 100 analysts and more than 3000 consultants, to help its clients, ranging from Fortune 1000 companies to small and medium-sized enterprises, easily grasp the expansive industry data and help them in formulating market and business strategies, which ensure that they remain ahead of the curve.

Contact Us:

Expert Market Research
Website: www.expertmarketresearch.com
Email: sales@expertmarketresearch.com
US & Canada Phone no: +1-415-325-5166
UK Phone no: +44-702-402-5790

*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.

Why Expert Market Research?

RIGHT PEOPLE

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

RIGHT METHODOLOGY

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

RIGHT PRICE

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

RIGHT SUPPORT

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

Similar Reports





NEWSLETTER